Van Eck Associates Corp Alnylam Pharmaceuticals, Inc. Transaction History

Van Eck Associates Corp

$70.4 Billion
Q2 2024

A detailed history of Van Eck Associates Corp transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Van Eck Associates Corp holds 60,938 shares of ALNY stock, worth $16.8 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

60,938

Previous 57,923 5.21%

Holding current value

$16.8 Million

Previous $8.66 Million 71.07%

% of portfolio

0.02%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$143.31 - $247.0 $432,079 - $744,705	3,015 Added 5.21%	60,938 $14.8 Million
Q1 2024 Apr 30, 2024	SELL	$146.51 - $198.2 $484,948 - $656,042	-3,310 Reduced 5.41%	57,923 $8.66 Million
Q4 2023 Feb 05, 2024	SELL	$151.41 - $196.57 $1.49 Million - $1.94 Million	-9,853 Reduced 13.86%	61,233 $11.7 Million
Q3 2023 Nov 08, 2023	SELL	$170.77 - $211.65 $1.18 Million - $1.46 Million	-6,882 Reduced 8.83%	71,086 $12.6 Million
Q2 2023 Aug 03, 2023	SELL	$185.01 - $212.05 $612,938 - $702,521	-3,313 Reduced 4.08%	77,968 $14.8 Million
Q1 2023 May 03, 2023	SELL	$182.66 - $235.53 $2.03 Million - $2.61 Million	-11,099 Reduced 12.01%	81,281 $16.3 Million
Q4 2022 Feb 08, 2023	BUY	$185.53 - $241.31 $4.17 Million - $5.43 Million	22,484 Added 32.17%	92,380 $22 Million
Q3 2022 Oct 27, 2022	SELL	$138.54 - $232.0 $5.48 Million - $9.17 Million	-39,546 Reduced 36.13%	69,896 $14 Million
Q2 2022 Aug 03, 2022	BUY	$120.42 - $169.29 $1.14 Million - $1.6 Million	9,436 Added 9.44%	109,442 $16 Million
Q1 2022 May 10, 2022	BUY	$127.18 - $173.91 $177,034 - $242,082	1,392 Added 1.41%	100,006 $16.3 Million
Q4 2021 Jan 26, 2022	BUY	$159.56 - $209.29 $943,478 - $1.24 Million	5,913 Added 6.38%	98,614 $16.7 Million
Q3 2021 Nov 03, 2021	SELL	$169.75 - $207.73 $4.74 Million - $5.8 Million	-27,921 Reduced 23.15%	92,701 $17.5 Million
Q2 2021 Aug 10, 2021	BUY	$128.63 - $176.89 $2.62 Million - $3.6 Million	20,368 Added 20.32%	120,622 $20.4 Million
Q1 2021 May 13, 2021	SELL	$126.83 - $175.69 $630,979 - $874,057	-4,975 Reduced 4.73%	100,254 $14.2 Million
Q4 2020 Feb 09, 2021	BUY	$122.97 - $147.0 $2.31 Million - $2.76 Million	18,790 Added 21.74%	105,229 $13.7 Million
Q3 2020 Nov 12, 2020	SELL	$121.19 - $165.49 $2.98 Million - $4.06 Million	-24,559 Reduced 22.13%	86,439 $12.6 Million
Q2 2020 Aug 10, 2020	BUY	$104.21 - $156.44 $2.5 Million - $3.75 Million	23,994 Added 27.58%	110,998 $16.4 Million
Q1 2020 May 12, 2020	SELL	$93.12 - $133.99 $2.6 Million - $3.74 Million	-27,922 Reduced 24.3%	87,004 $9.47 Million
Q4 2019 Feb 13, 2020	BUY	$74.51 - $124.23 $289,471 - $482,633	3,885 Added 3.5%	114,926 $13.2 Million
Q3 2019 Nov 08, 2019	BUY	$70.9 - $87.82 $467,372 - $578,909	6,592 Added 6.31%	111,041 $8.93 Million
Q2 2019 Aug 07, 2019	SELL	$65.86 - $92.79 $1.37 Million - $1.93 Million	-20,824 Reduced 16.62%	104,449 $7.58 Million
Q1 2019 May 13, 2019	BUY	$72.76 - $93.45 $671,429 - $862,356	9,228 Added 7.95%	125,273 $11.7 Million
Q4 2018 Feb 12, 2019	BUY	$62.67 - $88.33 $289,660 - $408,261	4,622 Added 4.15%	116,045 $8.46 Million
Q3 2018 Nov 13, 2018	BUY	$87.52 - $122.67 $2.91 Million - $4.08 Million	33,228 Added 42.49%	111,423 $9.75 Million
Q2 2018 Aug 13, 2018	BUY	$88.31 - $107.8 $966,994 - $1.18 Million	10,950 Added 16.28%	78,195 $7.7 Million
Q1 2018 May 11, 2018	SELL	$115.92 - $148.54 $2.26 Million - $2.89 Million	-19,454 Reduced 22.44%	67,245 $8.01 Million
Q4 2017 Feb 12, 2018	SELL	$114.49 - $139.98 $7.84 Million - $9.59 Million	-68,486 Reduced 44.13%	86,699 $11 Million
Q3 2017 Nov 09, 2017	BUY	$72.53 - $118.27 $1.97 Million - $3.21 Million	27,135 Added 21.19%	155,185 $18.2 Million
Q2 2017 Aug 11, 2017	BUY	N/A	128,050	128,050 $10.2 Million

Others Institutions Holding ALNY

# of Institutions

614

Shares Held

108M

Call Options Held

2.33M

Put Options Held

2.17M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Alnylam Pharmaceuticals, Inc. Transaction History